Summary
The TriMark Cancer Biomarker 2008 Conference has been organized to provide a critical examination of the latest in cancer diagnosis, as well as to provide insight from key industry leaders concerning cutting-edge technology platforms. This conference will also provide a forum for leaders in cancer biomarkers to share ideas, network with other delegates and advance understanding of the potential of new cancer detection technologies. The agenda will include:
Who Should Attend:
• Cancer diagnostics company representatives.
• In vitro diagnostic companies management and R&D directors.
• Biotechnology companies.
• Medical devices manufacturers.
• Diagnostic laboratory directors and staff.
Leaders from the Following Areas Will Greatly Benefit from Attending:
• Clinical Laboratory leaders.
• Hospital CFOs and CSOs.
• Physicians.
• Cancer diagnostics developers.
• Business development leaders.
• Strategic planning and development personnel.
• Technology development.
• Marketing.
• Research and development.
Key Themes:
• A critical examination of key emerging biomarker technologies for cancer diagnostics.
• Formation of successful alliances.
• Application of emerging technologies to cancer diagnostics.
• Transitioning from laboratory in vitro diagnostics to clinical management of cancer patients.
• The emerging role of cancer diagnostic tests in personalized medicine.
• The intersection of genomics and cancer diagnostics with personalized medicine.
Questions Answered in the TriMark Conference:
• What will the cancer diagnostics market be worth by the end of the decade?
• Which market key segments will drive cancer diagnostics market growth?
• Which new technologies will reach the cancer diagnostics market in the next 2-3 years?
• How is technology innovation impacting the dynamics and direction of the diagnostics industry?
• How can clinical labs bring new cancer diagnostic tests to patent care?
• What are the key challenges in gaining acceptance of new technologies by users, payers and regulators?
• How is technology innovation facilitating the transition of new cancer diagnostics testing into standard healthcare practice?
Top Five Reasons to Attend the TriMark Conference:
• Discover the cancer biomarkers sectors with the greatest prospective growth, ensuring you can successfully align your future strategies with predicted success.
• Evaluate the competitive dynamics of the cancer biomarkers market and understand the changing relationship between IVD companies and the cancer diagnostics testing sector.
• Identify the key players in the cancer biomarkers market, recognize lucrative partnering opportunities and benchmark your strategies against the leading players.
• Assess opportunities and challenges faced by diagnostic companies in gaining acceptance of innovative technologies by payers, regulators and users.
• Understand the factors driving growth of the cancer biomarkers market.
Registration Fees for the Conference:
• Early-Bird Registration Fee is $295 until April 30, 2008.
• Standard Registration Fee is $395 on and after May 1, 2008.
• At-the-Door Fee $500 on June 16, 2008 (subject to seating availability).
Register at http://www.trimarkpublications.com/conferences/
About TriMark Publications, LLC
Based in New York City, TriMark Publications is a global leader in biotechnology, healthcare and life sciences publishing. For more information, please visit http://www.trimarkpublications.com/conferences/.
For more information visit:
http://www.trimarkpublications.com/conferences/